Information Portal
Your trusted source for understanding and managing chronic lung diseases.
Taking control of your lung health starts with the right information.
Do you, or someone you know, suffer from a chronic lung disease? Are you a healthcare professional working in this field?
This information portal has been designed to provide reliable information on common chronic lung diseases.
Choose one of the following categories to get started:
Explore our education platform designed for healthcare professionals:
What's New in Chronic Lung Diseases:
Unlock COPD Insights:
November Awareness Campaign
Join us in recognizing COPD Awareness Month this November. Explore a wealth of educational content, access free resources, and benefit from exclusive course discounts designed for healthcare and exercise professionals.
Season 4 of The Expand Podcast is finally here!
Join us as we dive into the world of COVID-19 while unlocking the secrets not just of respiratory health, but other diseases as well.
We have prepared 6 episodes to study this condition from different perspectives, such as hypertension, immunosuppression, endocrinology, primary care, long COVID, and more.
Join our mailing list
Get the latest updates on Chronic Lung Diseases
Whether you’re a patient or healthcare professional, our regular updates will keep you informed on the latest research, treatments, and news.
By subscribing, I hereby agree and consent to the Terms of Use and the Privacy Policy and accept to be contacted via email by Respiplus.You can unsubscribe from the mailing list or change your preferences at any point.
Lung Cancer and COPD: Understanding the Connection
COPD raises lung cancer risk independently of smoking history. A 2024 meta-analysis found 1.76 times higher risk. The red flags and who to screen.
Lung Cancer Symptoms, Diagnosis and Screening in Canada
Nearly half of lung cancers in Canada are diagnosed late. The symptoms to watch for, the four steps of diagnosis, and who qualifies for screening.
Types of Lung Cancer: NSCLC, SCLC and Subtypes
Non-small cell lung cancer makes up 80-85% of cases in Canada. The two main types, their subtypes, and the biomarkers that decide treatment.
Lorlatinib in Practice: A Two-Year Case in ALK+ NSCLC
Weight gain, hyperlipidemia, edema and mild CNS changes over two years, with disease control maintained. Identify early, escalate proportionally, communicate clearly.
When to Refer: Multidisciplinary Care for Patients on Lorlatinib
Clear referral thresholds for neurology, psychiatry, cardiology, radiation oncology and tertiary centres in ALK+ NSCLC, while maintaining oncologic oversight.
Clinical Tools for Monitoring and Follow-Up
AE checklists, lipid monitoring, cognitive screening and symptom tracking. Practical tools that make follow-up systematic rather than reactive.
Sequencing After Progression in ALK+ Disease
The question is not whether the patient has progressed, but where and how. Interpreting isolated CNS, oligoprogressive and widespread systemic progression.
Dosing and Dose Modification Strategies
Start at 100 mg, interrupt early, reduce strategically. Dose reduction in early weeks did not compromise PFS or intracranial outcomes.
Hyperlipidemia and Metabolic Effects on Lorlatinib
Hypercholesterolemia occurs in 70–75% of patients on lorlatinib, with median onset around 15 days. Monitoring schedules and preferred statins by interaction profile.
Brain Metastasis in ALK+ Disease
In ALK+ NSCLC the brain is often involved at diagnosis, not late. Why CNS efficacy must be a primary treatment selection criterion, and what to monitor.